Level D· Scientific groundwork from lab and animal studiesNarrative ReviewPubMed

Potentiating the naturally occurring process for repair of damaged heart.

Li M., Ng SC.

Narrative Review on Cardiovascular Disease, published in Curr Pharm Des (2014) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Curr Pharm Des (2014)
Country
United Arab Emirates
Reported sample size
—
Source database
PubMed
PMID
23844738
DOI
10.2174/13816128113199990447
Citations
2

Abstract (original English)

This article reviews the current progresses in application of both exogenous and endogenous progenitor cells/stem cells for cardiac repair, and the current understanding of the naturally-occurring process for physiological myocyte turnover and possibly cardiac repair. In particular the development of methods for potentiating the naturally-occurring mechanism for substantial repair of pathologically damaged cardiac tissues is discussed. In the last decade, tremendous efforts to identify both exogenous and endogenous progenitor cells/stem cells possessing capacities of differentiating into cardiac lineages have been made for potential cardiac repair. Although many impressive progresses have been made in the application of differently sourced progenitor cells/stem cells, such as embryonic stem cells (ESCs), induced pluripotent stem cell (iPS), bone marrow-derived mesenchymal stem cells (MSCs), skeletal myoblasts (SMs), umbilical cord blood cells (UCBs), residential cardiac stem cells (CSCs), cardiac resident fibroblasts (CRFs), or adipose tissue-derived stem cells (ASCs) for repair of damaged heart, however, inevitable controversies exist concerning: (i) the immune compatibility of the exogenous donor progenitors/stem cells, (ii) the tumorigenicity with ESCs and iPS, and (iii) the efficiency of these exogenous or endogenous progenitors/ stem cells to acquire cardiac lineages to re

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsCell DifferentiationEmbryonic Stem CellsHumansMyocardial InfarctionMyocytes, CardiacPluripotent Stem CellsRegenerationStem Cell Transplantation

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research